Nektar Therapeutics (NKTR) — Analysis Summary
Nektar Therapeutics (NKTR) has a market cap of $1.36B with year-over-year revenue growth of -43.9%. Net margin stands at -297.1%. The stock trades at a P/E ratio of -8.7.
Key Takeaways
- Revenue changed -43.9% year-over-year
- Net margin of -297.1%
- P/E ratio of -8.7
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, NKTR posted revenue growth of -43.9% and trades at a P/E of -8.7.
Nektar Therapeutics (NKTR)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -257.8% — severe operating losses
Net margin at -287.8% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
63
Headquarters
SAN FRANCISCO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.